These 10 Stocks Lost This Much Today

3. Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals fell by 19.01 percent on Friday to end at $490.28 apiece as investor sentiment was dampened by the shocking failure of its potential treatment for chronic obstructive pulmonary disease (COPD) during one of its late-stage trials.

According to the company, the first trial of the Phase 3 study for the efficacy of itepekimab in adult former smokers with COPD met the primary target of showing a 27-percent reduction in the worsening symptoms after 52 weeks. However, the second trial failed to meet the same endpoint, having reduced by only 2 percent during the same study period.

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN), along with its partner, Sanofi, said they are reviewing the data and will discuss with regulatory authorities to evaluate next steps.

“Certain people with COPD are in desperate need of new treatment options, especially those who continue to experience exacerbations despite being on maximal therapy, and we remain committed to discussing these data with regulatory agencies to evaluate our path forward,” said Sanofi Head of Research and Development Houman Ashrafian.